Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $300000.0.

  • Revolution Medicines' Amortizatization of Intangibles changed 0.0% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year decrease of 2138.33%. This contributed to the annual value of $44.6 million for FY2024, which is 10069.8% up from last year.
  • Latest data reveals that Revolution Medicines reported Amortizatization of Intangibles of $300000.0 as of Q3 2025, which was down 0.0% from $300000.0 recorded in Q2 2025.
  • Revolution Medicines' 5-year Amortizatization of Intangibles high stood at $15.2 million for Q1 2024, and its period low was $300000.0 during Q2 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $300000.0 (2021), whereas its average is $2.8 million.
  • As far as peak fluctuations go, Revolution Medicines' Amortizatization of Intangibles skyrocketed by 63037.23% in 2023, and later plummeted by 3560.09% in 2025.
  • Over the past 5 years, Revolution Medicines' Amortizatization of Intangibles (Quarter) stood at $979000.0 in 2021, then rose by 20.74% to $1.2 million in 2022, then skyrocketed by 630.37% to $8.6 million in 2023, then grew by 2.24% to $8.8 million in 2024, then crashed by 96.6% to $300000.0 in 2025.
  • Its Amortizatization of Intangibles was $300000.0 in Q3 2025, compared to $300000.0 in Q2 2025 and $9.8 million in Q1 2025.